1. Background {#s0005}
=============

During the last decades adverse consequences from non-medical prescription opioid use (NMPOU) have increased dramatically, such as in the United States, causing widespread public health problems ([@b0040], [@b0145], [@b0200]). Researchers have described the occurrence of an American opioid epidemic. Among other factors, this may partly be due to the lowering of restrictions on the prescription of opioids for treatment of chronic non-cancer pain in the late 1990's ([@b0040], [@b0145]), and the promotion, in 1997--2002, of opioids by the pharmaceutical industry, leading to a 10-fold rise in prescriptions during this period ([@b0090]). The National Survey on Drug Use and Health (NSDUH) suggested that in 2016, 91.8 million US civilian, noninstitutionalized adults (34%) used prescription opioids; among whom 11.5 million (4%) misused them ([@b0210]). Researchers suggest, however, that an increasing awareness of NMPOU has made diversion and abuse of prescription opioids plateau and decrease in the last five years ([@b0060], [@b0240]). The numbers of heroin overdose-related deaths have escalated 4-fold in the US between 2010 and 2015 ([@b0090]), and although there was a slight decrease in heroin use in 2017 ([@b0210]), the transition from NMPOU to heroin abuse is a significant risk that should be considered, as available data indicates ([@b0050], [@b0060], [@b0090], [@b0135], [@b0240]). While NMPOU is far from a US-only problem, direct comparisons between the US and European Union, for example, are difficult because of methodological differences in the drug abuse surveillance systems ([@b0180]). While the most commonly used illicit opioid in Europe is heroin; however, a number of sources suggest that illicit use of synthetic opioids in Europe is increasing ([@b0085], [@b0180]). In several European countries, non-heroin opioids represent the most common form of opioid use ([@b0085]).

Tramadol is a central acting analgesic, and it is unique in that it acts through both opioid receptors and monoamine reuptake mechanisms. Tramadol inhibits serotonin and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. Due to tramadol's modulation of norepinephrine and serotonin reuptake, the substance has specific risks which are atypical to standard opioid class pharmaceuticals. These adverse effects include tachycardia, hypertension, seizures and serotonergic syndrome ([@b0015], [@b0030], [@b0125], [@b0225], [@b0250]). The affinity of tramadol for the µ opioid receptor is low, approximately 10-fold less than that of codeine. The main metabolite of tramadol, O-desmethyltramadol (M1), has about 300-fold higher affinity to the µ opioid receptor than the parent compound. Conversion of tramadol to M1 is catalyzed by cytochrome P450 (CYP) 2D6. There is significant variability in the efficiency and amount of CYP2D6 enzymes among individuals. Phenotypic variations in CYP2D6 can be classified as poor metabolizers (PM) with little or no CYP2D6 function, Intermediate metabolizers (IM), extensive metabolizers (EM) and ultra-metabolizers (UM). UM and EM have approximately a 40% greater serum concentration of the active metabolite M1. Subsequently, UM and EM experience a stronger opioid response and a higher risk for addiction and overdose compared with PM and EM. PM have a 20% higher serum concentration of tramadol, and are at risk for adverse effects related to a hyperserotonergic state and seizures ([@b0125], [@b0170]).

Tramadol is recommended as a basic analgesic for the treatment of moderate to severe acute pain ([@b0030], [@b0100], [@b0115], [@b0165]). In 2014, tramadol was added by the Drug Enforcement Administration (DEA) to category IV of scheduled drugs ([@b0075]). Researchers have found that tramadol enhances the reward system, thereby confirming its abuse potential ([@b0010], [@b0205]). Before the placement as a category IV scheduled drug tramadol was, by physicians, often considered to have a low potential for abuse and dependence with low adverse effects ([@b0010], [@b0115]). Mainly due to tramadol's inhibitory effects on the serotonin and norepinephrine systems, research has shown potential use of tramadol as an antidepressant ([@b0195], [@b0230]). Also, tramadol has an effect on the ejaculation latency in males with premature ejaculation. This is mainly due to tramadol's inhibition of the serotonin transporter (SERT). The effect appears to be effective in the treatment of premature ejaculation ([@b0080], [@b0150]); however, long-term tramadol abuse may be associated with poor sperm quality and hyperprolactinemia ([@b0095]).

An increasing attention has been paid to adolescent use of tramadol, although markedly lower compared to the widespread use of cannabis; the prevalence of cannabis use is about five times that of other substances, and the most frequently used illicit drug among adolescents. In 15- to 16-year-old students from 35 European countries, 18% reported having used cannabis at least once. The use of illicit drugs other than cannabis (MDMA/ecstasy, amphetamine, cocaine, methamphetamine and hallucinogens) was far lower, with an overall lifetime prevalence of 5%. Lifetime use of sedatives or tranquilizers without a doctor's prescription was reported by an average of 6% of students ([@b0085]). In 2016, about 891,000 adolescents in the United States aged 12--17 misused opioids in the past year. This number corresponds to 3.6% of adolescents misusing opioids in the past year ([@b0215]). The knowledge of tramadol abuse among adolescents is limited. In the Middle East, studies confirm the widespread use of tramadol among adolescents ([@b0025], [@b0020]), and in a study conducted in Sweden, Olsson et al. ([@b0185]) concluded that tramadol misuse may represent a novel pattern of substance use among adolescents. While tramadol thereby appears to be a relatively novel pattern of NMPOU, including in young individuals, there is little research examining the characteristics of this increase and individuals reporting tramadol misuse. Therefore, the present study aimed to study characteristics of treatment-seeking adolescents reporting misuse of tramadol, compared to their counterparts seeking treatment for other substance use, and to study characteristics of primary tramadol users specifically, compared to the remaining treatment-seeking cohort.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

The present study is an observational, non-interventional, cross-sectional study of tramadol use and its correlates within a cohort of adolescents and young adults seeking treatment at an out-patient facility for the treatment of substance use disorders in the young.

2.2. Clinical setting {#s0020}
---------------------

Maria Malmö is an outpatient treatment center in Malmö, Sweden, aimed at adolescents and young adults with substance use disorders and problematic substance use. The upper age limit is 25 years, while there is no formal lower age limit. The treatment center is administered by both the social services and the health care services, and offers psychosocial and medical assessment, support and treatment, related to the abuse of drug and alcohol. The catchment area of the facility is the city of Malmö with approximately 340,000 inhabitants, the third largest city of Sweden. In Sweden, use and any handling of classified substances (addictive prescription drugs and illicit drugs) is illegal.

2.3. Measures {#s0025}
-------------

All adolescents included in the present study were assessed by staff at the center with the structured interview instrument Ung-DOK ('Young-DOC'), which is the adolescent version of the DOC system. DOC (referred to in Swedish as DOK) stands for 'documentation and evaluation regarding treatment of alcohol and drug abusers' ([@b0130]). In the present study, data from this instrument were used in order to compare tramadol users to other individuals seeking treatment for a substance use disorder at the unit. The DOC instrument has an overall structure similar to that of the ASI (Addiction Severity Index), which is designed to measure the patient's status in seven functional domains, and which characterizes and quantifies the severity of the multiple health and social problems ([@b0160]). Ung-DOK is a semi-structured interview method aimed specifically for adolescents with various forms of alcohol and drug problems ([@b0055]). The Ung-DOK interview contains questions within the following life domains: housing and financial support, occupation, tobacco use, alcohol use, drug use, treatment history, criminality, childhood, exposure to violence, family and relationships, physical health and mental health.

In the Ung-DOK questionnaire, primary drug is defined in the manual as the substance being the major problem to the individual at treatment start and/or the main reason why an individual seeks treatment, as judged by the interviewer when considering her/his own judgment and the opinion of the patient. Also, according to the interview manual, other substances are reported if they are judged from the patient assessment to constitute a problem. One exception here is that below 18 years of age, any alcohol use is always reported as a problem, whereas alcohol for majors is discussed and judged to be a problem or not depending on the interview. In the present paper, 'use' is defined as the reported problematic use of a substance according to the manual. The drugs specified in the Ung-DOK questionnaire are alcohol, cannabis, amphetamine, cocaine, ecstasy, LSD and other hallucinogenes, heroin, methadone, buprenorphine, GHB, spice (synthetic cannabinoids), solvents, benzodiazepines, other opioid and/or sedative drugs (also including analgesics without known addictive potential), and anabolic androgenic steroids. The category 'other opioid and/or sedative drugs' (reported by 14 percent of tramadol users and 10 percent of non-users, the difference being non-significant) was not further considered in the study. Also, the very rare non-opioid substances (GHB, and anabolic-androgenic steroids, both reported by one percent and non-significant across study groups), as well as LSD/hallucinogenes (non-significant across study groups, p = 0.636, reported by 7%) were not included for further analyses. The same goes for synthetic cannabinoids (reported by 17%, non-significant across study groups, p = 0.057), as this drug was reported virtually only during the first half of the study period, following a short-term rise in the use of this combination of drugs in the present community). Further, an 'other' category is available for other substances, i.e. a very wide 'other' group difficult to interpret, and not further considered in the present study, with the exception that the occurrence of tramadol from this category was coded specifically, and led to the grouping of tramadol users and non-users in the present study.

The frequency of drug use in Ung-DOK, for each problematic substance used, is reported in the categories no use, single occasion, one day a week or less, 2--3 days a week, 4--6 days a week, and daily. In the present study, the history of substance use during lifetime was used. Thus, the comparison of tramadol users and non-users refers to lifetime use vs non-use. In the secondary analysis, patients reporting tramadol as their primary drug were compared to all other individuals in the cohort. Other variables used in the present study include age, gender, whether parents are born outside Scandinavia, current (past three months) accommodation, past-three-month occupation, regular current tobacco smoking, lifetime history of having been convicted for crime, lifetime history of depression, anxiety/distress, difficulty controlling violent behavior, and current ongoing contact with adult or child and adolescent psychiatry.

2.4. Procedures {#s0030}
---------------

The Ung-DOK interviews were conducted by staff from Maria Malmö outpatient treatment center in Malmö, Sweden. The interviews were executed during 1st of January 2014 to the 31st of December 2017. All data from Ung-DOK were anonymous for the research group. The study was conducted only through retrospective analyses of Ung-DOK questionnaire data, and involved no repeated contact with the patients and therefore no informed consent procedure. The study was approved by the Regional Ethics Committee in Lund file number 2018/165.

2.5. Participants {#s0035}
-----------------

Included patients were those seeking treatment at the Maria Malmö outpatient facility in Malmö, Sweden, and who had been interviewed with the Ung-DOK questionnaire, from 1st of January 2014 to the 31st of December 2017. During that period, a total of 635 Ung-DOK intake interviews were conducted. The completed Ung-DOK interviews were transferred to a database. A total of 107 interviews were identified as being the second or third interview of the same individual and therefore excluded, and two interviews were incomplete and therefore excluded from the study. This resulted in 526 Ung-DOK intake interviews being included in the study.

2.6. Statistics {#s0040}
---------------

The analyses compared characteristics of individuals seeking treatment with a history of problematic tramadol use, compared to the remaining patients. In a secondary analysis, those reporting tramadol to be their primary drug were compared to all patients reporting other primary drugs. Cross tabulation and multivariable logistic regression methods (the latter including variables which were significantly associated with tramadol use in the non-adjusted analyses) were used in the software SPSS (IBM SPSS statistics version 24). Pearson's chi-squared test was applied for categorical variables for calculating differences between groups (Fisher's exact test was used for the analyses of associations with the substances rarely reported). Results were considered significant if the p value was less than 0.05. For use of other substances than tramadol, any problem use (as defined by the Ung-DOK manual) during lifetime was used, however, as the problem use of cannabis was reported by nearly all participants, the variable addressing cannabis was set to describe frequent use (four times a week or more) vs all other clients. As the frequency variable is available for the past-three-month period, the variable distinguishing frequent from non-frequent cannabis use was studied for the past three months.

3. Results {#s0045}
==========

A total of 388 respondents (74%) were men and 138 (26%) were women. The age varied between a minimum of 13 years to a maximum of 24 years. The median age was 17 years and mean age 18 years. A total of 431 (82%) had some form of occupation (school, work or work practice), whereas 93 (18%) had no form of occupation. Fourty-seven percent (n = 247) had both their parents born in Scandinavia (Sweden, Norway and Denmark) and 279 (53%) had one or both parents born outside the Scandinavian countries.

The most commonly reported primary drug was cannabis, reported by 425 subjects (81%), and 369 (70%) reported use of at least one drug other than the primary drug. Median age of onset of substance use was 15 years for cannabis (n = 507), 16 for tramadol (n = 162), 17 for amphetamine (n = 71), 17 for cocaine 17 (n = 133), 17 for benzodiazepines (n = 73), and 18 years of age for ecstasy (n = 105).

Among the 526 subjects, 162 (31%) stated any problematic tramadol use. Among them, past-three-month use was reported by 88 individuals (17%), and past-month use was reported by 58 individuals (11%). In binary comparison, lifetime tramadol use was significantly associated with age, occupation last three months, one or both parents born outside Scandinavia, ever being convicted, regular use of tobacco, a lifetime history of anxiety or distress, no ongoing contact with child or adult psychiatry, lifetime problematic use of cocaine, ecstasy, amphetamine, and benzodiazepines, as well as frequent cannabis use (on four days a week or more during the past three months, [Table 1](#t0005){ref-type="table"}).Table 1Comparison of tramadol users and non-users. Chi-squared tests for categorical variables and *t*-test for age.Tramadol use (n = 162), n (%)No tramadol use (n = 364)Missing datap-valueAge (Mean)18.7517.8900.001Gender Women40 (25)98 (27) Men122 (75)266 (73)00.591Occupation last three months120 (74)311 (86)20.001Own accommodation or with guardians last three months139 (86)315 (87)10.763Both parents born in Scandinavia61 (38)186 (51)00.004Ever convicted67 (43)70 (21)39\<0.001Regular use of tobacco145 (90)266 (74)3\<0.001Ever been depressed123 (76)244 (68)80.062Ever had anxiety or distress129 (80)248 (69)80.012Ever had difficulties controlling violent behavior86 (53)160 (45)120.089Ongoing contact with child or adult psychiatry30 (19)103 (28)00.017Problematic use, lifetime --alcohol131 (81)275 (77)70.327 --cannabis159 (98)348 (96)00.149 --cocaine65 (40)68 (19)0\<0.001 --ecstasy43 (27)62 (17)00.012 --amphetamine38 (23)33 (9)0\<0.001 --benzodiazepines41 (25)32 (9)0\<0.001 --heroin6 (4)9 (2)00.411[1](#tblfn1){ref-type="table-fn"} --buprenorphine4 (2)2 (1)00.076[1](#tblfn1){ref-type="table-fn"} --methadone1 (1)0 (0)00.308[1](#tblfn1){ref-type="table-fn"} --cannabis use 4 days a week or more82 (51)126 (35)00.001[^1]

In logistic regression, tramadol use remained significantly associated with having one or both parents born outside Scandinavia, ever being convicted, regular use of tobacco, absence of ongoing contact with child or adult psychiatry, and lifetime problematic use of cocaine, amphetamine, and benzodiazepines ([Table 2](#t0010){ref-type="table"}).Table 2Associations with tramadol use in logistic regression.VariablesORLowerUpperp-valueGender0.9050.5301.5480.716Age0.9580.8681.0580.397Occupation last three months1.5660.8572.8620.145Both parents born in Scandinavia0.5030.3240.7790.002Ever convicted1.6871.0222.0220.041Regular use of tobacco2.6461.4454.8440.002Ever had anxiety or distress1.2340.7292.0890.433Ongoing contact with child or adult psychiatry0.5270.3030.9150.023Problematic cocaine use2.0371.1723.5400.012Problematic ecstasy use0.5930.3071.1470.131Problematic amphetamine use2.4981.2475.0030.010Problematic benzodiazepines use2.5701.3824.7780.003Problematic cannabis use 4 days a week or more1.3890.8922.1620.145

Six percent (n = 29) reported tramadol to be their primary drug. In binary comparison, tramadol as primary drug use was significant associated with problematic cocaine use and significantly and negatively associated with cannabis use on four days a week or more ([Table 3](#t0015){ref-type="table"}). In logistic regression, reporting tramadol as the primary drug use remained significantly associated with problematic cocaine use, and significantly and negatively associated with reporting frequent cannabis use (four days a week or more, [Table 4](#t0020){ref-type="table"}).Table 3Comparison of patients with primary drug tramadol use, and patients with other primary drugs. Chi-squared tests for categorical variables and *t*-test for age.VariablesTramadol primary drug (n = 29), n (%)Tramadol not primary drug (n = 497), n (%)Missing datapProblematic cocaine use12 (41)121 (24)00.040Problematic cannabis use 4 days a week or more6 (21)202 (41)00.033Table 4Associations with having tramadol as primary drug, in logistic regression.ORLowerUpperp-valueProblematic cocaine use2.7121.3755.9660.013Problematic cannabis use 4 days a week or more0.3140.1230.8030.016

4. Discussion {#s0050}
=============

The aim of this study was to examine which factors distinguish adolescents using tramadol from other substance-abusing adolescents in an outpatient treatment setting. The main findings are the significant rate of polydrug use associated with tramadol use, the association between tramadol use and a history of criminal conviction, and sociodemographic factors related to tramadol use, such as having one or both parents born outside Scandinavia. In addition, the tramadol use group was less likely to report an ongoing psychiatric treatment contact.

One significant finding was the higher rates of polysubstance use in the tramadol group, compared to other treatment-seeking clients. Adolescents reporting tramadol use showed a significantly increased risk of problematic use of other illicit drugs. Even when controlling for other measures of clinical severity, we demonstrated a higher likelihood of tramadol users reporting problematic use of cocaine, amphetamine and benzodiazepines. The result is in line with previous conclusions from [@b0185] in the same setting. In contrast, however, in the present study, in the sub-analysis assessing factors associated with the primary use of tramadol (as the main drug), the association with problematic cocaine use remained, although the prevalence of frequent cannabis use decreases for this category. This may indicate that in the group defining their tramadol use to be their main type of drug use, the extensive use of cannabis -- reported by nearly all subjects in the study -- tends to be partially replaced by tramadol intake. Altogether, the higher rates of polysubstance use in the proportion of treatment-seeking clients who reported tramadol use, calls for increased attention in this patient group, with this relatively recent trend in tramadol misuse, to their risk of also co-using or having used other substances.

Polysubstance use, defined as using multiple substances within a specified period of time is an understudied characteristic of adolescents substance use and more research is needed. [@b0255] found a positive association between illicit drug use and nonmedical use of prescription medications, and polydrug use is more common among young people receiving treatment as previous studies shows ([@b0245], [@b0255]). For tramadol specifically, [@b0175] studied the prevalence of tramadol misuse in a sample of Iranian adolescents and assessed the relationship between tramadol and other substance use. They found tramadol to be a factor related to adolescents' alcohol, cannabis and ecstasy use, thereby a factor associated with a polysubstance use pattern.

The onset age of tramadol is 16 years and was preceded only by cannabis. This may be seen as a novel pattern of substance use, since tramadol only has been available in Scandinavia since the late 90's and started to appear at the present outpatient clinic during the last decade. Polydrug use with adolescent onset increases the risk for lifelong drug use and psychiatric disorders ([@b0035], [@b0155]). More longitudinal studies are needed to gain a better understanding of the association between tramadol use and transition into more prevalent polydrug use. Also, although the link between tramadol and use of other substances was one of the most important findings of the study, it cannot be excluded that the use of tramadol, as well as the use of other substances, are the result of a third factor not assessed here, or that being prone to try different substances would also increase the risk of trying tramadol as one substance among these. Thus, the direction of the association between tramadol use and other substance use in the present study cannot be established. However, the age of initiation of use was lower for tramadol than for most other substances, and in the consideration of this novel type of opioid use pattern, it may be of importance to note that its clinical picture is likely to involve a more extensive polysubstance pattern than in other young individuals seeking substance use disorder treatment.

4.1. Criminal convictions {#s0055}
-------------------------

One finding of the present paper was the association between tramadol use and ever being convicted for crime. Most researchers agree that crime and drug abuse are related. [@b0065] find that juvenile drug use is significantly associated with a criminal career, and [@b0235] argues that youth who engage in comorbid delinquency and early onset of substance misuse may be at greater risk of subsequent criminal involvement and substance misuse, compared to youth who only engage in crime or only misuse substances. In the current study, even when controlling for age and gender, there was a clear association between tramadol use and a history of being convicted. From the Ung-DOK material, it is not possible to determine what type of crime the adolescents is convicted of, and all adolescents in the study receive treatment for different degrees of drug abuse and therefore, to the same extent, may have had a risk of becoming arrested for drug possession or drug-related offenses.

Tramadol's unique properties in that it acts through opioid receptors and monoamine reuptake mechanisms could have an impact on the adolescent's behavior. As the antidepressant mood elevation effect ([@b0230]) in combination with the modulating role of opioid systems on anxiety ([@b0045]) could facilitate a more daring behavior, it cannot be excluded that these properties of tramadol may have implications for mechanisms leading to crime convictions as assessed in the present study. More research is needed to better understand the underlying factors that contribute to the association between tramadol use and crime convictions, and whether this is explained by characteristics of the substance itself or by shared risk factors in the population, or both.

4.2. Socioeconomic factors {#s0060}
--------------------------

Tobacco, alcohol, cannabis and polysubstance use are common behaviors among adolescents, particularly those experiencing socioeconomic disadvantage. [@b0190] argue that adolescents with lower socioeconomic position generally initiated substance use at a younger age. [@b0220] found that immigrant status was associated with less persistent opioid use. [@b0120] state that opioid use is more common among non-Nordic immigrants. Having one or both parents born in another country could lead to problems for families' integration into society, which in turn can lead to low socioeconomic status. Language difficulties also may cause problems regarding education. Unemployment is generally higher among immigrants, which also could affect the socioeconomic status. [@b0005] argue that teens with lower socioeconomic status may be more likely to live in communities were illicit substances are more accessible. More research is needed to gain a deeper understanding of the socioeconomic factors of tramadol use.

4.3. Lower rates of psychiatric treatment contacts {#s0065}
--------------------------------------------------

Polydrug users are at elevated risk of psychological distress ([@b0140]). In line with the main findings we anticipated to find an increased psychiatric comorbidity in the tramadol use group. Contrary to our hypotheses, there was no significant association between tramadol use adolescents and other substance-using adolescents with respect to psychiatric symptoms. Additionally, the tramadol use group had less ongoing contact with psychiatric care. This is concurrent with [@b0185] findings that tramadol use patients did not display more extensive comorbidity problems than other substance-abuse adolescents. The antidepressant properties of tramadol ([@b0195], [@b0230]) and its effects on psychiatric symptoms may be a contributing factor and merits more research in order to further understand the underlying reasons for this. Eighty percent of the respondents stated cannabis as the primary drug. Cannabis use is often associated with major depression, mood disorders, anxiety and psychotic disorder ([@b0070], [@b0105], [@b0110]). In the present study preliminary rates of psychiatric comorbidity in this group were high. Thus, it may be difficult to demonstrate significant differences between the groups.

5. Implications {#s0070}
===============

Considering the global spread of opioids and the early age of onset for tramadol, and considering the present findings of tramadol becoming the second most prevalent drug after cannabis in young treatment-seeking patients, it is important to screen for tramadol use. If tramadol use is detected, screening should be continued as there is a strong significance for use of other illicit substances. This applies for all relevant authorities within healthcare, social services and the judiciary system. Thus, even though use of different substances in this group may not happen during the same episodes in life, as almost half of lifetime tramadol users did not report the use of that substance during the past three months, those reporting any tramadol use in their lifetime can still be seen as a group with a high risk of engaging in polysubstance use. In addition, it is of great importance for prescribing physicians to take the abuse potential of tramadol under consideration when prescribing tramadol.

6. Strengths and limitations {#s0075}
============================

To our knowledge this is the first study that systematically examines the characteristics of tramadol users in an entire population of treatment-seeking adolescents and young adults. However, this study has limitations, including the fact that the study is based only on one city in Sweden; thus, generalizability to other setting cannot necessarily be assumed. Here, further studies in other geographical settings may be needed. Also, all measures were based on self-reports, such that misclassification and under-reporting of sensitive behaviors such as substance use can occur, a matter that should be kept in mind when interpreting the findings. Also, the study has an entirely cross-sectional design, and more prospective research is needed to examine the longitudinal associations of tramadol use.

7. Conclusions {#s0080}
==============

Tramadol use is a novel pattern among treatment seeking adolescents in the present setting. The tramadol-using adolescents differ from others substance-abuse adolescents in that they showed a significant increased risk of also using other illicit drugs, and they are at greater extent in contact with the judicial system, but not with the psychiatric treatment system. More research is needed to understand the underlying mechanisms of adolescent tramadol use.
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[^1]: Fisher's exact test.
